English
繁體中文
ALL
2022
2021
2020~2015
Sep 10, 2018
SyneuRx’s SNS Patent Applications Have Been Granted in Taiwan and in the US.
May 22, 2017
First Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia
May 11, 2017
First Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trial
Apr 04, 2016
FDA Approves SyneuRx’ IND Application for Late Phase Clinical Development of a Mild Dementia Treatment
Dec 19, 2015
SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults
